News & Events

• December 18, 2018
  

  Critical Path Institute Encouraged by FDA to Move Forward on Type 1 Diabetes Biomarker Initiative

  Biomarker potentially could identify individuals at risk of developing T1D TUCSON, Ariz., December 18, 2018 — Critical Path Institute (C-Path) announced today that its Type 1 Diabetes (T1D) Consortium has received a positive response to its Letter of Intent (LOI) from the U.S. Food and Drug Administration (FDA) detailing the FDA’s decision to accept the...
• March 20, 2017
  

  Critical Path Institute Launches Type 1 Diabetes Consortium

  March 20, 2017 Critical Path Institute Launches Type 1 Diabetes Consortium Tucson, Ariz., March 20, 2017 –Critical Path Institute (C-Path) is pleased to announce the launch of the Type 1 Diabetes (T1D) Consortium. Funded by The Leona M. and Harry B. Helmsley Charitable Trust; Janssen Research & Development, LLC; JDRF International; and Sanofi, the T1D...